|Description||ACT 178882 is a novel Renin inhibitor (IC50= 1.4 nM).|
|Synonyms||ACT 178882, ACT-178882, ACT178882; MK-1597; MK1597; MK 1597; (3R,4S)-N-[[2-chloro-5-(2-methoxyethyl)phenyl]methyl]-N-cyclopropyl-4-[6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]pyridin-3-yl]piperidine-3-carboxamide|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||764.3±60.0 ℃ at 760 Torr|
Remikiren is a renin inhibitor originated by Roche in 1996. But clinical trials for the treatment of Heart failure and Hypertension was discontinued.
PD 132002 is a renin inhibitor originated by Pfizer. In Dec 2001, clinical trials for Hypertension in USA was discontinued.
ACT 178882 is a novel Renin inhibitor (IC50= 1.4 nM).
Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site tow...
VTP-27999 2,2,2-trifluoroacetate is an alkyl amine Renin inhibitor, useful for Hypertension and End-Organ Diseases.
CP 84364 is an active metabolite of CP-80794 which is a Renin inhibitor.
CI 992 is a renin inhibitor originated by Pfizer. Preclinical trials for Hypertension in USA was discontinued in 1994.
PD 125967 is a renin inhibitor which may be useful for treatment of essential hypertension.